A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

NCT00212875 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Anemia

Interventions

DRUG: epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]